teclistamab,daratumumab,pomalidomide,talquetamab
genmab,janssen
['mmsm', 'trimm-2', 'talquetamab', 'daratumumab']
aa3/talquetamab + daratumumab in rrmm: trimm-2 results
- tal 0.4 qw or 0.8 qow +dara
- high risk cyto:12%
- emd: 26%
- lot: 5
- triple rrmm: 60%, penta rrmm: 28%, bcma exposure: 58%
#mmsm #myeloma #medtwitter #meded #asco23 #usmirc 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter